Physician profile
Elvis Jacome
NPI 1720138365
$10,834.05
in general payments reported to CMS, 2019-2025
30 companies · $2,923 in 2025
The $2,923 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,428 · 2022: $2,232 · 2023: $1,617 · 2024: $2,634 · 2025: $2,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,745 · Education: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,745.04 |
| Education | $429.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,659.54 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $1,346.42 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $821.04 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $735.46 | 2022-2025 | Adbry, Spevigo |
| Janssen Biotech, INC. | $731.90 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $720.75 | 2021-2025 | |
| Lilly USA, LLC | $636.02 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $613.15 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $505.62 | 2023-2025 | |
| Amgen INC. | $481.27 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $431.96 | 2021-2025 | Bimzelx |
| Alkermes, INC. | $353.07 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $350.52 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $303.32 | 2021-2025 | Nemluvio |
| Vertex Pharmaceuticals Incorporated | $274.41 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $254.96 | 2023-2024 | Vtama |
| Octapharma USA, INC. | $118.20 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.75 | 2023-2025 | Spevigo, Cyltezo |
| Organon LLC | $79.56 | 2025 | Vtama |
| Biofrontera INC. | $71.92 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Krystal Biotech INC | $64.57 | 2024-2025 | Vyjuvek |
| Journey Medical Corporation | $46.77 | 2023-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $31.88 | 2023-2025 | Valchlor |
| Sanofi-Aventis U.S. LLC | $31.04 | 2021 | |
| Genzyme Corporation | $21.27 | 2025 | |
| Kyowa Kirin, INC. | $19.18 | 2024 | Poteligeo |
| Springworks Therapeutics, INC. | $18.24 | 2025 | Gomekli |
| Tactile Systems Technology INC | $12.35 | 2021 | |
| Pfizer INC. | $11.82 | 2022 | |
| Biowound Solutions, INC. | $3.09 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elvis Jacome listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.